Oramed (NASDAQ: ORMP) gains $18M, declares $0.25 special dividend

Rhea-AI Filing Summary

Oramed Pharmaceuticals Inc. reported that it has received an $18 million payment from Scilex Holdings Inc., which represents full satisfaction of Scilex’s obligations under their Option Agreement. This adds a significant amount of cash to the company.

The company’s board also approved a cash dividend of $0.25 per share to reward stockholders, for a total distribution of approximately $10.5 million based on the current shares outstanding. The dividend will be paid on January 26, 2026 to stockholders of record as of January 16, 2026, and will be funded from the company’s surplus capital.

Positive

• $18 million cash payment received from Scilex Holdings Inc., fully satisfying obligations under the Option Agreement.
• Board approved a $0.25 per share cash dividend, returning approximately $10.5 million of surplus capital to stockholders.

Negative

• None.

Insights

Equity analyst

Oramed secures $18M cash and returns about $10.5M via a special dividend.

Oramed Pharmaceuticals Inc. has strengthened its balance sheet by receiving an $18 million payment from Scilex Holdings Inc., described as full satisfaction of obligations under their Option Agreement. This is a clear cash inflow and removes uncertainty around that contractual receivable.

At the same time, the board approved a $0.25 per share cash dividend, totaling roughly $10.5 million based on the current share count. This indicates a willingness to return surplus capital to stockholders rather than retain all of the new cash, which some investors may view as a sign of balance sheet strength and limited immediate internal cash needs.

The dividend will be paid on January 26, 2026 to holders of record on January 16, 2026, giving a clear timeline for this capital return. Future filings can provide more detail on the company’s post-dividend cash position and how remaining funds will support operations and any strategic initiatives.

false 0001176309 0001176309 2026-01-07 2026-01-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 7, 2026

ORAMED PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

delaware		001-35813		98-0376008
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1185 Avenue of the Americas, Third Floor, New York, New York		10036
(Address of Principal Executive Offices)		(Zip Code)

844-967-2633

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
Common Stock, par value $0.012		ORMP		The Nasdaq Capital Market, Tel Aviv Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 7, 2026, Oramed Pharmaceuticals Inc. (the “Company”) issued a press release announcing it has received an $18 million payment from Scilex Holdings Inc., representing full satisfaction of obligations under the Option Agreement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Additionally, the press release announced that the Company’s Board of Directors has approved a cash dividend payment of $0.25 per share to reward stockholders. The dividend will result in an aggregate distribution of approximately $10.5 million based on the current number of shares outstanding. The dividend will be paid on January 26, 2026, to stockholders of record as of January 16, 2026. The dividend will be funded with surplus capital. 

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated January 7, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ORAMED PHARMACEUTICALS INC.
	By:	/s/ Nadav Kidron
	Name:	Nadav Kidron
	Title:	President and CEO

January 7, 2026

2

FAQ

What payment did Oramed Pharmaceuticals (ORMP) receive from Scilex?

Oramed Pharmaceuticals Inc. received an $18 million payment from Scilex Holdings Inc., which represents full satisfaction of Scilex’s obligations under the Option Agreement.

Did Oramed Pharmaceuticals (ORMP) declare a cash dividend?

Yes. Oramed’s Board of Directors approved a cash dividend of $0.25 per share to reward stockholders.

How much will Oramed distribute in total dividends?

Based on the current number of shares outstanding, the $0.25 per share dividend will result in an aggregate distribution of approximately $10.5 million.

When is the record date and payment date for Oramed’s dividend?

The dividend will be paid on January 26, 2026 to stockholders of record as of January 16, 2026.

How will Oramed fund the announced cash dividend?

The company stated that the $0.25 per share dividend will be funded with surplus capital.

What is the significance of the Scilex payment for Oramed?

The $18 million payment from Scilex is described as full satisfaction of obligations under the Option Agreement, providing cash to Oramed and closing out that obligation.